Search

everythinglearnresearchcommunity

for

Search:↓

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

New lipid/fiber microplexes improve mRNA therapy for degenerative diseases by enhancing cell function and treatment effectiveness.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Finasteride increases CD8+ T cells in BPH tissues.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

FCO2 laser is a better treatment for alopecia areata than intralesional steroids.

High-dose steroid pulse therapy effectively regrows hair in severe multifocal alopecia areata.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

Baricitinib may effectively treat nail changes in alopecia areata.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Both treatments for alopecia areata are equally effective and safe.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.